Astellas Pharma Inc.

    Jurisdiction
    Japan
    LEI
    529900IB708DY2HBBB35
    ISIN
    JP3942400007 (4503.T)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - General

    Scores

    InsiderPie Expert Score
    51 / 100
    Even with peer group:
    51 / 100
    Fair value (Benjamin Graham formula)
    €5.38 60.8% overvalued
    Financial strength (Piotroski F-Value)
    7 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Read full profile

    Fundamentals

    Net revenue
    €11.05B
    Gross margin
    78.2%
    EBIT
    €346.51M
    EBIT margin
    3.1%
    Net income
    €293.15M
    Net margin
    2.7%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    N/A N/A
    N/A N/A
    N/A N/A

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    ¥39.00
    Ex date
    Payment date
    Dividend payout ratio
    254.2%

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Add to watchlist

    Notifications